Allervax Ragweed peptide therapeutic data

IMUL reported positive results in its Phase II/III study of Allervax Ragweed in 960 patients at 27 centers in the U.S. and Canada.

A total of 960 patients were randomized to receive either placebo (n=320) or four doses of 750 µg (n=320) at either two doses/week for two weeks or one dose/week for four weeks administered prior to the start of the ragweed season. There was no difference in results between those 750 µg groups. Other patients received two doses of 750 µg or doses of 75 µg. ...